Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Kelly

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
World Journal of Clinical Oncology|March 26, 2021
Overview of recent advances in metastatic triple negative breast cancerDavid O'Reilly, Maha Al Sendi, Catherine M Kelly
Breast Care (Basel, Switzerland)|June 15, 2017
Therapeutic Advances and New Directions for Triple-Negative Breast CancerEleni Andreopoulou, Catherine M Kelly, Hayley M McDaid
Expert Opinion on Drug Safety|June 15, 2012
Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancerGeraldine O'Sullivan Coyne, Janice Walsh, Catherine M Kelly
Expert Opinion on Drug Safety|July 18, 2014
Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinomaTomas G Lyons, Grainne M O'Kane, Catherine M Kelly
International Journal of Cancer|May 20, 2021
Oligometastatic breast cancer: Are we there yet?Maha AlSendi, David O'Reilly, Youssef H Zeidan, et al.
The Oncologist|November 3, 2010
Estrogen and HER-2 receptor discordance between primary breast cancer and metastasisLajos Pusztai, Giuseppe Viale, Catherine M Kelly, et al.
JCO Oncology Practice|November 12, 2024
Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCOCatherine M Kelly, Kathleen E Bennett, Caitriona Cahir, et al.
BMC Cancer|October 3, 2020
The psychosocial determinants of quality of life in breast cancer survivors: a scoping reviewMichael G Culbertson, Kathleen Bennett, Catherine M Kelly, et al.
The Oncologist|July 8, 2016
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast CancerLibero Santarpia, Giulia Bottai, Catherine M Kelly, et al.
The Oncologist|April 28, 2010
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerDaphne T Tsoi, Miho Inoue, Catherine M Kelly, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
World Journal of Clinical Oncology|March 26, 2021
Overview of recent advances in metastatic triple negative breast cancerDavid O'Reilly, Maha Al Sendi, Catherine M Kelly
Breast Care (Basel, Switzerland)|June 15, 2017
Therapeutic Advances and New Directions for Triple-Negative Breast CancerEleni Andreopoulou, Catherine M Kelly, Hayley M McDaid
Expert Opinion on Drug Safety|June 15, 2012
Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancerGeraldine O'Sullivan Coyne, Janice Walsh, Catherine M Kelly
Expert Opinion on Drug Safety|July 18, 2014
Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinomaTomas G Lyons, Grainne M O'Kane, Catherine M Kelly
International Journal of Cancer|May 20, 2021
Oligometastatic breast cancer: Are we there yet?Maha AlSendi, David O'Reilly, Youssef H Zeidan, et al.
The Oncologist|November 3, 2010
Estrogen and HER-2 receptor discordance between primary breast cancer and metastasisLajos Pusztai, Giuseppe Viale, Catherine M Kelly, et al.
JCO Oncology Practice|November 12, 2024
Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCOCatherine M Kelly, Kathleen E Bennett, Caitriona Cahir, et al.
BMC Cancer|October 3, 2020
The psychosocial determinants of quality of life in breast cancer survivors: a scoping reviewMichael G Culbertson, Kathleen Bennett, Catherine M Kelly, et al.
The Oncologist|July 8, 2016
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast CancerLibero Santarpia, Giulia Bottai, Catherine M Kelly, et al.
The Oncologist|April 28, 2010
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerDaphne T Tsoi, Miho Inoue, Catherine M Kelly, et al.
Pageof 7